Risk adjusted net present value: What is the current valuation of Avidity Biosciences’s AOC-1020?

AOC-1020 is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Facioscapulohumeral Muscular Dystrophy (FSHD).

‘Best Medical Schools’ Rankings Delayed for Second Year in a Row

For a second year in a row, the “Best Medical Schools” rankings from U.S. News & World Report have been delayed. This year’s rankings were

April 10, 2024

Gut microbiome linked to eczema in infancy

A new study has revealed important associations between the gut microbiome and eczema in infancy and has established the basis for the potential prevention and

August 31, 2023

New study suggests higher buprenorphine doses could help save lives

Individuals with opioid use disorder who were prescribed a lower buprenorphine dose were 20% more likely to discontinue treatment than those on a higher dose,

September 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.